

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10550444	
	Filing Date		2006-06-01	
	First Named Inventor	George C. PRENDERGAST		
	Art Unit	1626		
	Examiner Name	Laura Lynn Stockton		
Attorney Docket Number		3882-P03161US01		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10550444
Filing Date	2006-06-01
First Named Inventor	George C. PRENDERGAST
Art Unit	1626
Examiner Name	Laura Lynn Stockton
Attorney Docket Number	3882-P03161US01

1	M. MASUDA et al., "Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGPR-related pathways of signal transduction", Journal of Experimental Therapeutics and Oncology, 2: 350-359 (2002)	<input type="checkbox"/>
2	Lin JEN-KUN, Database BIOSIS, "Cancer chemoprevention by the polyphenols through modulating signal transduction pathways", Archives of Pharmacal Research (Seoul), 25: 561-571 (2002)	<input type="checkbox"/>
3	C.M. COVER et al., "Indole-3-Carbinol and Tamoxifen Cooperate to Arrest the Cell Cycle of MDF-7 Human Breast Cancer Cells", Cancer Research, 59: 1244-1251 (1999)	<input type="checkbox"/>
4	R. JAKSE et al., A simple synthesis of aplysinopsin analogues by dimethylamine substitution in N,N-(dimethylamino) methyldene derivatives of five-membered heterocycles", Tetrahedron, 57: 8395-8403 (2001)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.